Lani J. Davies

This paper describes a method to label affibodies with radiometals without using chelators, demonstrating stable metal binding and retention under various conditions.

This study uses fragment-based drug design to identify novel heparanase inhibitors, resulting in compounds with improved potency for potential therapeutic applications.

This paper shows that mutating nanobodies to create cysteine motifs enables specific binding of theranostic metals like bismuth, gallium, and indium for medical imaging and therapy.